Why is Astec Lifescienc falling/rising?

As of 04-September, Astec Lifesciences Ltd is experiencing a decline in its stock price, currently at 850.00, which reflects a decrease of 2.35 (-0.28%). The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 3.33% during this period. Additionally, the stock has shown negative returns over various time frames, including a 1-month drop of 3.59% and a year-to-date decline of 15.42%. The company has reported operating losses and has declared negative results for the last five consecutive quarters, which has contributed to its weak long-term fundamental strength. The high Debt to EBITDA ratio of 2.64 times and a low Return on Equity of 9.96% further indicate challenges in profitability and debt servicing, making the stock a strong sell. In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as the Sensex has gained 0.80% over the past week while Astec Lifesciences Ltd has lost 1.21%. This consistent underperformance against the benchmark over the last three years, coupled with a significant drop in investor participation—evidenced by a 51.67% decrease in delivery volume—highlights the stock's declining appeal. The liquidity remains adequate for trading, but the overall sentiment around the stock is negative, driven by its risky profile and poor historical returns, which have seen a 29.37% decline over the past year.